PROVIDER RESOURCES
PROVIDER RESOURCES
Embedded Files
NEW APPT [15m] ...15-29 ...30-44 ...45-59 ...60-74 [RARE]
NEW APPT [15m] ...15-29 ...30-44 ...45-59 ...60-74 [RARE]
MOST COMMON NEW =
MOST COMMON NEW =
30-44 MIN = 99203 OR 45-59 MIN (FOR 3+ DX) = 99204
30-44 MIN = 99203 OR 45-59 MIN (FOR 3+ DX) = 99204
Modifier 25 for visits w/ procedures
Modifier 25 for visits w/ procedures
E/M levels are selected based on either Medical Decision Making (MDM) or Total Time spent on the date of the encounter.
New Patient Visits
New Patient Visits
A "New Patient" has not received any professional services from the provider (or another provider of the exact same specialty/subspecialty in the same group) within the past 3 years.
99201 (DELETED): This code was retired in 2021. New billers often see it in old manuals, but it is no longer valid. If a visit is "Level 1," you must now use 99202.
99202 (Straightforward MDM): 15–29 minutes. Used for minor issues (e.g., a simple localized muscle strain).
[ 99203 (Low MDM): 30–44 minutes]
99204 (Moderate MDM): 45–59 minutes. The "workhorse" for pain management, as patients usually have multiple chronic conditions or require complex treatment planning.
99205 (High MDM): 60–74 minutes. Used for extremely complex cases or when extensive records from multiple outside specialists must be reviewed.
Established / Follow-Up Visits
Established / Follow-Up Visits
99211 (Minimal Complexity): Often called the "Nurse Visit."
The Nuance: This is the only E/M code that does not require a physician to be in the room. It is used for services like a blood pressure check or a quick dressing change by a nurse under physician supervision. It does not have a time requirement in the descriptor.
99212 (Straightforward MDM): 10–19 minutes. Used for very brief follow-ups where the condition is stable (e.g., a quick check on a healing trigger point site).
99213 (Low MDM): 20–29 minutes.
[ 99214 (Moderate MDM): 30–39 minutes ] Standard for regular follow-ups for chronic pain patients with fluctuating symptoms.
MORE DETAILS ....
✅ PASS (Audit-Safe) Example
Assessment/MDM (E/M):
New patient evaluated for lumbar radiculopathy with 6-month history, worsening despite PT and medications. Independent history, exam, and MRI review performed. Treatment options discussed. Decision made today to proceed with ESI due to persistent symptoms and functional limitation.
Billing:
99204-25 (New patient E/M)
62323 (ESI)
Why it passes:
✔ Separate clinical decision
✔ Not pre-scheduled solely for injection
✔ Clear medical necessity
❌ FAIL (Audit Risk) Example
❌ FAIL (Audit Risk) Example
Documentation:
Patient presents for scheduled lumbar ESI. Consent obtained. Procedure performed without complication.
Billing:
99204-25 + ESI ❌
Why it fails:
✘ No distinct evaluation
✘ No new decision-making
✘ Visit solely procedural
⚠️ BORDERLINE (High Risk)
⚠️ BORDERLINE (High Risk)
Documentation:
Reviewed prior notes. Patient continues pain. Proceeded with planned ESI.
Issue:
Minimal MDM; decision appears pre-determined.
Florida Audit-Safe Checklist
Florida Audit-Safe Checklist
New complaint or worsening condition
Separate history + exam + MDM
Explicit statement: “Decision to perform ESI made today”
Avoid phrases like “patient here for scheduled injection”
One-Line Safe Phrase
“Following a comprehensive new-patient evaluation, the decision was made today to proceed with ESI due to failure of conservative management.”
Follow-up [10m] ...10-19 ...20-29 ...30-39 ...40-49 [RARE]
Follow-up [10m] ...10-19 ...20-29 ...30-39 ...40-49 [RARE]
MOST COMMON FOLLOWUP =
MOST COMMON FOLLOWUP =
20-29 MIN = 99213 OR 30-39 MIN (FOR 2+ DX) = 99214
20-29 MIN = 99213 OR 30-39 MIN (FOR 2+ DX) = 99214
Modifier 25 for visits w/ procedures
Modifier 25 for visits w/ procedures
E/M levels are selected based on either Medical Decision Making (MDM) or Total Time spent on the date of the encounter.
New Patient Visits
New Patient Visits
A "New Patient" has not received any professional services from the provider (or another provider of the exact same specialty/subspecialty in the same group) within the past 3 years.
99201 (DELETED): This code was retired in 2021. New billers often see it in old manuals, but it is no longer valid. If a visit is "Level 1," you must now use 99202.
99202 (Straightforward MDM): 15–29 minutes. Used for minor issues (e.g., a simple localized muscle strain).
[ 99203 (Low MDM): 30–44 minutes]
99204 (Moderate MDM): 45–59 minutes. The "workhorse" for pain management, as patients usually have multiple chronic conditions or require complex treatment planning.
99205 (High MDM): 60–74 minutes. Used for extremely complex cases or when extensive records from multiple outside specialists must be reviewed.
Established / Follow-Up Visits
Established / Follow-Up Visits
99211 (Minimal Complexity): Often called the "Nurse Visit."
The Nuance: This is the only E/M code that does not require a physician to be in the room. It is used for services like a blood pressure check or a quick dressing change by a nurse under physician supervision. It does not have a time requirement in the descriptor.
99212 (Straightforward MDM): 10–19 minutes. Used for very brief follow-ups where the condition is stable (e.g., a quick check on a healing trigger point site).
99213 (Low MDM): 20–29 minutes.
[ 99214 (Moderate MDM): 30–39 minutes ] Standard for regular follow-ups for chronic pain patients with fluctuating symptoms.
MORE DETAILS ....
✅ PASS (Audit-Safe) Example
Assessment/MDM (E/M):
New patient evaluated for lumbar radiculopathy with 6-month history, worsening despite PT and medications. Independent history, exam, and MRI review performed. Treatment options discussed. Decision made today to proceed with ESI due to persistent symptoms and functional limitation.
Billing:
99204-25 (New patient E/M)
62323 (ESI)
Why it passes:
✔ Separate clinical decision
✔ Not pre-scheduled solely for injection
✔ Clear medical necessity
❌ FAIL (Audit Risk) Example
❌ FAIL (Audit Risk) Example
Documentation:
Patient presents for scheduled lumbar ESI. Consent obtained. Procedure performed without complication.
Billing:
99204-25 + ESI ❌
Why it fails:
✘ No distinct evaluation
✘ No new decision-making
✘ Visit solely procedural
⚠️ BORDERLINE (High Risk)
⚠️ BORDERLINE (High Risk)
Documentation:
Reviewed prior notes. Patient continues pain. Proceeded with planned ESI.
Issue:
Minimal MDM; decision appears pre-determined.
Florida Audit-Safe Checklist
Florida Audit-Safe Checklist
New complaint or worsening condition
Separate history + exam + MDM
Explicit statement: “Decision to perform ESI made today”
Avoid phrases like “patient here for scheduled injection”
One-Line Safe Phrase
“Following a comprehensive new-patient evaluation, the decision was made today to proceed with ESI due to failure of conservative management.”
ICD10
ICD10
ICD-10 Quick Reference Outline
ICD-10 Quick Reference Outline
I. Head & Face
I. Head & Face
Atypical Facial Pain: G50.1
Headaches:
Cervicogenic/Suboccipital: R51
Cluster (non-intractable): G44.009
Occipital Neuralgia: M54.81
Spinal: G97.1
Tension: G44.209
TMJ Dysfunction: M26.60
Trigeminal Neuralgia: G50.0
II. Cervical Spine (Neck)
II. Cervical Spine (Neck)
Cervicalgia: M54.2
DDD / Herniation:
High (C2-C4): M50.31 (DDD) / M50.21 (Hern)
Mid (C5-C7): M50.32 (DDD) / M50.22 (Hern)
C7/T1: M50.33 (DDD) / M50.23 (Hern)
Radiculopathy: * Cerv: M54.12 | Cerv-Thor: M54.13
2/2 Herniation: M50.11 (High), M50.12 (Mid), M50.13 (C7/T1)
Spondylosis: M47.812 (Std) | M47.22 (w/ Radic)
Other: Dystonia (M43.6), Facet Synd (M54.02), failed back (M96.1), Stenosis (M48.02), Spondylolisthesis (M43.12), Whiplash (S13.4xxA/D), Strain (S16.1xxA/D)
III. Thoracic Spine (Mid-Back)
III. Thoracic Spine (Mid-Back)
Pain: M54.6
DDD / Herniation: * Thoracic: M51.34 (DDD) / M51.24 (Hern)
Thor-Lumbar: M51.35 (DDD) / M51.25 (Hern)
Fracture (Path): M80.88 (OP) | M48.54xA/D (Thor) | M48.55xA/D (T/L)
Radic: M54.14 | 2/2 Hern: M51.14 (Thor), M51.15 (T/L)
Nerves/Vessels: Intercostal Neuro (G58.0), TOS (G54.0)
Other: DISH (M48.10), Scoliosis (M41), Stenosis (M48.04), Myelopathy (M47.14), Syrinx (G95.0)
IV. Lumbar Spine (Low Back)
IV. Lumbar Spine (Low Back)
Lumbago (LBP): M54.5
DDD / Herniation:
Lumbar: M51.36 (DDD) / M51.26 (Hern)
L/S: M51.37 (DDD) / M51.27 (Hern)
Radiculopathy:
Lumbar: M54.16 | L/S: M54.17
2/2 Hern: M51.16 (Lum), M51.17 (L/S)
Stenosis (Central): * Lumbar: M48.061 (w/o Claud) | M48.062 (w/ Claud)
Foraminal: M99.63 (Facet/Spondy) | M99.73 (Disc/Soft tissue)
Other: AS (M45.6), Bertolotti’s (Q76.49), Facet Synd (M54.06), Spondy (M43.16), Muscle Spasm (M62.830)
V. Sacrum / Pelvis / Lower Extremity
V. Sacrum / Pelvis / Lower Extremity
Sacrum: Coccydynia (M53.3), SI Joint Pain (M12.9), Sacroiliitis (M46.1)
Hip/Thigh: * OA Hip: M25.752 (L) / M25.751 (R)
Trochanteric Bursitis: M70.62 (L) / M70.61 (R)
Piriformis/Sciatica: G57.02 (L) / G57.01 (R)
Meralgia Paresthetica: G57.12 (L) / G57.11 (R)
Knee: OA (715.16), Chondromalacia (M22.42 L / M22.41 R)
Ankle/Foot: Plantar Fasciitis (M72.2), Morton’s Neuroma (G57.62 L / G57.61 R), Tarsal Tunnel (G57.52 L / G57.51 R)
Misc LE: CRPS 1 (G90.52_), Phantom Pain (G54.6)
VI. Upper Extremity
VI. Upper Extremity
Shoulder: * Frozen Shldr: M75.02 (L) / M75.01 (R)
Impingement: M75.42 (L) / M75.41 (R)
Rotator Cuff Strain: S46.012 (L) / S46.011 (R)
Elbow: Tennis (M77.1_), Golfer's (M77.0_)
Wrist/Hand: * Carpal Tunnel: G56.02 (L) / G56.01 (R)
Cubital Tunnel: G56.22 (L) / G56.21 (R)
De Quervain’s: M65.4, Trigger Finger: M65.30
VII. Systemic / Miscellaneous
VII. Systemic / Miscellaneous
Rheum: RA (M06.9), SLE (M32.9), PMR (M35.3), Gout (M10.00), AS (M45._)
Psych: Anxiety (F41.1), Depression (F33.9), Insomnia (G47.00)
General: Fibromyalgia (M79.1), Chronic Pain Synd (G89.4), Myalgia (M79.7), Peripheral Neuro (G60.9), Vitamin D Def (E55.9)
Skin: Paresthesia (R20.2), Hypoesthesia (R20.1), Hyperesthesia (R20.3)
DDIs
DDIs
More ICD10 | CPT | Drug-Drug Interactions
More ICD10 | CPT | Drug-Drug Interactions
ICD 10
https://thepainsource.com/icd-10-codes-for-physical-medicine-and-pain-management/
CPT
https://www.aapc.com/codes/cpt-codes-range
https://www.cms.gov/medicare/physician-fee-schedule/search
https://thepainsource.com/homepage/cpt-codes-pmr-pain-management-billing-and-coding/
DDIs
DDIs
Modifier 59 vs 51
Modifier 59 vs 51
Practical Guidance for Your Examples
Practical Guidance for Your Examples
✅ Use Modifier 59
✅ Use Modifier 59
Shoulder joint + subacromial bursa injection
Occipital nerve block + trigger point injections
CESI + occipital nerve block
Facet injection + PRP injection (distinct intent)
⚠️ Modifier 51 — payer dependent
⚠️ Modifier 51 — payer dependent
SI joint injection + trochanteric bursa injection
Knee injection + knee brace
Lumbar facet injection + SI joint injection
❌ Do NOT use Modifier 51
❌ Do NOT use Modifier 51
Add-on facet levels (e.g., 64494, 64495)
Imaging guidance codes
Brace DME codes (L-codes)
Modifier 59 — Distinct Procedural Service
Meaning:
A procedure that is normally bundled but is separate and distinct due to different site, structure, or clinical intent.
I call this the "don't bundle me code" - Explain in the treatment plan the assessment and plan of multiple pain generators.
When to use:
NCCI edits indicate bundling
Procedures are:
Different anatomic regions
Different pain generators
Separate clinical objectives
Key rule:
✔ Modifier 59 overrides bundling edits
✔ Strong documentation is required
Example (appropriate):
Shoulder joint injection + subacromial bursa injection
CPT 20610
CPT 20610-59
Common pain examples where 59 is preferred:
CESI + occipital nerve block
Facet injection + trigger point injections
Joint injection + bursa injection in same region
Facet injection + PRP injection (if distinct intent)
Examples of documentation:
CESI + occipital nerve block: Cervical epidural targets nerve root compression; occipital block treats greater occipital nerve pain at posterior scalp.
Facet injection + trigger point injections: Facet injection treats zygapophyseal joints; trigger points target hyperirritable cervical or lumbar paraspinal muscles.
Joint injection + bursa injection: Joint injection treats intra-articular pathology; bursa injection treats periarticular inflammation in adjacent bursal structures.
Facet injection + PRP injection: Facet injection treats zygapophyseal joint inflammation; PRP targets adjacent degenerative ligamentous or capsular tissue for biologic healing.
BETTER:
CESI + Occipital Nerve Block A/P: Exam shows cervical radicular pain with limited ROM and positive Spurling, plus posterior scalp tenderness. Plan: 1. Cervical radicular pain CESI completed. 2. Occipital neuralgia occipital nerve blocks completed. Continue physical therapy, posture and sleep positioning discussed.
Facet Injection + Trigger Point Injections A/P: Exam reveals facet loading pain with extension and rotation and discrete paraspinal trigger points. Plan: 1. Facet mediated axial pain facet injections completed. 2. Myofascial pain trigger point injections completed. Continue physical or chiropractic therapy. Activity and posture discussed.
Joint Injection + Bursa Injection A/P: Exam shows painful joint range of motion with crepitus and focal periarticular bursal tenderness. Plan: 1. Intra articular joint pain joint injection completed. 2. Periarticular bursitis bursa injection completed. Activity modification discussed. Continue therapeutic exercise.
Facet Injection + PRP Injection A/P: Exam demonstrates facet mediated axial pain with imaging supported degeneration and capsuloligamentous instability. Plan: 1. Facet joint inflammation facet injection completed. 2. Degenerative soft tissue pain PRP injection completed. Continue physical therapy. Activity and posture discussed.
Thoracic Facet + Trigger Point A/P: s/p recent thoracic facet injection with partial axial pain relief. Exam shows focal myofascial tenderness lateral to left axillary thoracic paraspinals. Plan: 1. Thoracic facet pain previously treated. 2. Residual myofascial pain left thoracic trigger point injection completed. Continue physical or chiropractic therapy. Posture and sleep position discussed.
Pain Procedure codes below
Spinal & Epidural (Non-Pump)
62321: Cervical/Thoracic interlaminar epidural (with imaging).
62323: Lumbar/Sacral interlaminar epidural (with imaging).
64483: Transforaminal epidural; lumbar/sacral, single level.
64484: Transforaminal epidural; lumbar/sacral, each additional level.
64479: Transforaminal epidural; cervical/thoracic, single level.
64480: Transforaminal epidural; cervical/thoracic, additional level.
27096: Sacroiliac (SI) joint injection (with imaging).
62273: Injection of blood patch (epidural) for spinal headache.
64490: Facet joint injection; cervical/thoracic, level 1.
64491: Facet joint injection; cervical/thoracic, level 2.
64492: Facet joint injection; cervical/thoracic, level 3.
64493: Facet joint injection; lumbar/sacral, level 1.
64494: Facet joint injection; lumbar/sacral, level 2.
64495: Facet joint injection; lumbar/sacral, level 3.
Nerve Blocks (Diagnostic & Therapeutic)
64454: Genicular nerve block (Diagnostic knee block).
64405: Greater occipital nerve block.
64450: Peripheral nerve block
64505: Sphenopalatine ganglion (SPG) block (for headaches; migraines/facial pain).
64510: Stellate ganglion block.
64520: Lumbar/Thoracic sympathetic block.
64418: Suprascapular nerve block.
64420: Intercostal nerve block; single level.
64421: Intercostal nerve block; each additional level.
Radiofrequency & Destruction (Ablation)
64633: RFA facet nerve; cervical/thoracic, level 1.
64634: RFA facet nerve; cervical/thoracic, level 2 (add-on, each).
64635: RFA facet nerve; lumbar/sacral, level 1.
64636: RFA facet nerve; lumbar/sacral, level 2 (add-on, each).
64625: RFA of nerves innervating the SI joint.
64624: RFA of genicular nerves (Knee RFA).
Regenerative & Soft Tissue
0232T: Platelet-Rich Plasma (PRP).
Biller Note: Covers the blood draw, centrifuge, and injection.
20552: Trigger point injection; 1-2 muscle groups.
20553: Trigger point injection; 3+ muscle groups.
20550: Injection into single tendon sheath/ligament.
20551: Injection into single tendon origin/insertion.
20610: Large joint injection (shoulder, hip, knee).
20611: Large joint injection with ultrasound guidance.
5 Essential Billing Modifiers
-25 (Separately Identifiable E/M): Use when an office visit (99214) and a procedure (TPI) happen same-day.
-59 (Distinct Procedural Service): Use for two procedures at different sites (e.g., knee and shoulder).
-50 (Bilateral Procedure): Use for left and right sides.
-RT / -LT (Right/Left): Specific anatomic markers to avoid "duplicate" denials.
-KX (Requirements Met): Often required for Facet injections to prove failed conservative therapy.
Platelet-Rich Plasma (0232T): New billers often try to code the ultrasound (76942) or the joint injection (20610) separately to increase revenue. Do not do this. 0232T is a "global" Category III code. All imaging and the injection itself are bundled into this one code.
Corticosteroids (The "Anti-Inflammatories")
Injected for: Spinal epidurals, facet joints, large joints, and trigger points.
J3301: Triamcinolone Acetonide (Kenalog), per 10 mg
Frequency: Highest. The "gold standard" for joints and tendons due to its long-lasting, particulate nature.
J1100: Dexamethasone Sodium Phosphate, 1 mg
Frequency: High. Preferred for epidural injections because it is non-particulate, reducing the risk of embolic complications.
J1010: Methylprednisolone Acetate (Depo-Medrol), 1 mg
Frequency: Moderate. (Note: Formerly J1020/J1030/J1040). Widely used for joints and trigger points.
J0702: Betamethasone Acetate & Sodium Phosphate, 3 mg
Frequency: Moderate. Often used in specialized nerve blocks and facet injections.
J1094: Dexamethasone Acetate, 1 mg
Frequency: Low. A particulate version of Dexamethasone used less frequently than the sodium phosphate version.
Local Anesthetics & Buffers (The "Numbing Agents")
Injected for: Immediate pain relief, diagnostic nerve blocks, and "buffering" the sting.
J2001: Lidocaine HCl, 10 mg
Frequency: Highest. Used in almost every procedure to numb the skin or the target nerve.
J3490: Sodium Bicarbonate (8.4% solution)
Frequency: High. Mixed with local anesthetics to neutralize pH and reduce the "burn" during injection.
Non-Steroidal Anti-Inflammatories (NSAIDs)
Injected for: Acute flare-ups or at the end of a procedure.
J1885: Ketorolac Tromethamine (Toradol), 15 mg
Frequency: High. Often given as a "booster" IM injection for acute pain.
@T9 TP is T8; [T8->8/9,10/11.
@T10 TP is T9 .... [T9->9/10,10/11][T10->10/11, 11-12] [T11->11/12, 12/L1]
@ S1/ala is L5.
Cervical Stenosis: AP canal <10 mm, cord area <70 mm², CSF effacement, T2 cord signal.
Thoracic: AP canal <10 mm with cord compression or T2 signal.
Lumbar: Dural sac <75 mm², AP canal <10 mm, lateral recess <3–4 mm, foraminal fat loss.
- Cervical Spinal Stenosis
Central canal stenosis is suggested when the anteroposterior (AP) canal diameter is less than 10 mm (absolute) or 10–13 mm (relative). A spinal cord cross-sectional area < 70 mm² is strongly associated with myelopathy. Cord compression, loss of CSF signal, and T2 hyperintensity within the cord indicate clinically significant stenosis. Foraminal stenosis is present with loss of perineural fat and nerve root deformation.
- Thoracic Spinal Stenosis
Thoracic stenosis is less common and usually pathologic. Central canal stenosis is suspected when the AP canal diameter is < 10 mm, particularly with cord flattening or deformation. Disc–osteophyte complexes, facet hypertrophy, or ossification of the ligamentum flavum (OLF) causing cord compression are significant. T2 cord signal change implies chronic compression or myelopathy.
- Lumbar Spinal Stenosis
Central canal stenosis is defined by a dural sac cross-sectional area < 100 mm² (relative) and < 75 mm² (absolute). AP canal diameter < 10 mm supports the diagnosis. Lateral recess stenosis is present when the AP height < 3–4 mm with traversing nerve root impingement. Foraminal stenosis is identified by foraminal height < 15 mm, loss of perineural fat, or exiting nerve root compression.
- Key Imaging Correlates (All Regions)
Severity increases with facet hypertrophy, ligamentum flavum thickening > 4–5 mm, disc bulge/herniation, osteophytes, and dynamic narrowing on flexion/extension imaging. MRI is preferred for neural compression; CT better characterizes bony contributors.
I. Cervical Stenosis (C-Spine)
A. Normal sagittal canal diameter: 17–18 mm
B. Absolute stenosis: <10 mm sagittal diameter
C. Relative stenosis: <13 mm sagittal diameter
D. Torg–Pavlov ratio: canal diameter ÷ vertebral body diameter
1. Stenosis: <0.80 (standard)
2. Severe/athletes: <0.70
E. Kang MRI grading
1. Grade 0: No stenosis
2. Grade 1: >50% subarachnoid space obliteration, no cord deformity
3. Grade 2: Cord deformity, no signal change
4. Grade 3: T2 cord signal change (myelomalacia)II. Thoracic Stenosis (T-Spine)
A. Less common; no universally standardized grading system
B. Diagnostic threshold: AP canal diameter <10–12 mm or direct cord compression
C. Key indicators
1. OPLL or OLF causing canal narrowing
2. Central disc herniation with >50% canal compromiseIII. Lumbar Stenosis (L-Spine)
A. Primary metrics: dural sac cross-sectional area (DSCA) and nerve root morphology
B. Quantitative criteria
1. Relative stenosis: DSCA 75–100 mm² or AP diameter <12 mm
2. Absolute stenosis: DSCA <75 mm² or AP diameter <10 mm
C. Schizas MRI classification
1. Grade A (mild): CSF visible; rootlets dorsal
2. Grade B (moderate): Rootlets fill sac; CSF grainy
3. Grade C (severe): No visible rootlets; no CSF
4. Grade D (extreme): No rootlets; complete loss of posterior epidural fatIV. Comparison Summary
A. Cervical: Normal 17–18 mm; absolute <10 mm; Kang grading
B. Thoracic: Normal 12–14 mm; absolute <10 mm; cord compression/OPLL
C. Lumbar: Normal >15 mm; absolute <10 mm; Schizas classification
Ossification of the Posterior Longitudinal Ligament or Ligamentum Flavum
Research Studies Demonstrating Benefit with Platelet-Rich Plasma for Pain Management and Injuries
Multiple meta-analyses demonstrate that PRP reduces pain and improves function in knee osteoarthritis, with effects exceeding minimal clinically important differences (MCID) at several time points.
[1] A 2025 meta-analysis of 18 RCTs (1,995 patients) found PRP provided clinically significant pain relief at 3- and 6-month follow-up and functional improvement at all time points (1, 3, 6, and 12 months) compared to placebo.
[1] The benefit was influenced by platelet concentration, with high-platelet PRP (>1,000,000 platelets/µL) providing superior and more durable results.
A 2023 systematic review and meta-analysis of 24 RCTs (1,344 patients) confirmed PRP's effectiveness in improving VAS pain scores in knee osteoarthritis (MD = -1.03, 95% CI [-1.16, -0.9], p < 0.05).
[2] The same review found leukocyte-poor (LP) PRP was more effective than leukocyte-rich (LR) PRP for pain reduction.
Multiple studies demonstrate PRP superiority over hyaluronic acid for knee osteoarthritis, with significant improvements in pain at 6 and 12 months and better WOMAC function scores at 3, 6, and 12 months.
[3]
Lateral Epicondylitis (Tennis Elbow)
The most robust evidence for PRP in tendinopathy exists for lateral epicondylitis.
[4] A 2018 meta-analysis found patients treated with PRP for lateral epicondylitis reported significantly less pain in the long term (WMD, -1.39; 95% CI, -2.49 to -0.29; P = 0.01).
[5] Multiple randomized controlled trials have demonstrated positive responses to PRP injections for this condition.
Rotator Cuff Injuries
PRP demonstrates benefit when used as surgical augmentation for rotator cuff repairs, particularly for small- to medium-sized tears.
[6] A 2018 meta-analysis showed patients treated with PRP for rotator cuff injuries reported significantly less pain in the long term (WMD, -0.53; 95% CI, -0.98 to -0.09; P = 0.02).
[5] Meta-analysis suggests PRP may augment rotator cuff repairs, resulting in improved healing rates, reduced pain levels, and improved functional outcomes.
Chronic Tendinopathy After Failed Conservative Treatment
A 2025 systematic review specifically examining patients who failed conservative management found PRP significantly reduced pain at 6 months (MD: -0.83, 95% CI: -1.61 to -0.04) and 12 months (MD: -1.11, 95% CI: -2.10 to -0.12) compared to control treatments.
[7] This effect persisted at 24 months, though based on limited data.
Other Tendinopathies
Positive results have been demonstrated in randomized controlled trials for gluteus medius tendinopathy and plantar fasciopathy. [4] However, well-designed RCTs found no difference between PRP and saline injections for Achilles tendinopathy, and results for patellar tendinopathy have been mixed.
Safety Profile
PRP demonstrates an excellent safety profile with no significant increase in adverse events compared to other conservative treatments. A pooled analysis of 26 studies (1,051 patients) showed non-significant differences in adverse events between PRP and other treatments.
[3] Among studies reporting adverse events, there was no difference between treatment groups (7/241 versus 5/245; RR 1.31, 95% CI 0.48 to 3.59).[8]
Important Limitations
A 2014 Cochrane review concluded there was insufficient evidence to support routine use of PRP for musculoskeletal soft tissue injuries, citing heterogeneity in PRP preparation methods and study quality.
[8] The 2021 RESTORE trial, a high-quality RCT, found no significant benefit of PRP over placebo for knee osteoarthritis, highlighting ongoing controversy.
[9] Current American College of Rheumatology guidelines recommend against PRP due to very low-certainty evidence.
The American Journal of Sports Medicine. 2025. Bensa A, Previtali D, Sangiorgio A, et al.New
Frontiers in Medicine. 2023. Xiong Y, Gong C, Peng X, et al.
Journal of Pain Research. 2022. Hunter CW, Deer TR, Jones MR, et al.Guideline
Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine. 2021. Finnoff JT, Awan TM, Borg-Stein J, et al.Guideline
The American Journal of Sports Medicine. 2018. Chen X, Jones IA, Park C, Vangsness CT.
6.Platelet-Rich Plasma: Fundamentals and Clinical Applications.
Arthroscopy : The Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2021. Sheean AJ, Anz AW, Bradley JP.
Pain Medicine. 2025. Nadeau-Vallée M, Ellassraoui S, Brulotte V.New
8.Platelet-Rich Therapies for Musculoskeletal Soft Tissue Injuries.
The Cochrane Database of Systematic Reviews. 2014. Moraes VY, Lenza M, Tamaoki MJ, Faloppa F, Belloti JC.
The Journal of the American Medical Association. 2021. Bennell KL, Paterson KL, Metcalf BR, et al.
PROVIDER RESOURCES
PROVIDER RESOURCES
T9 medial branch → T9–10 & T10–11 facets
T10 medial branch → T10–11 & T11–12 facets
T11 medial branch → T11–12 & T12–L1 facets
T12 medial branch → T12–L1 & L1–L2 facets
L1 medial branch → L1–2 & L2–3 facets
L2 medial branch → L2–3 & L3–4 facets
L3 medial branch → L3–4 & L4–5 facets
L4 medial branch → L4–5 & L5–S1 facets
L5 dorsal ramus → L5–S1 facet (via branch to sacral ala/SI capsule)
📚 Reference: Bogduk N, Wilson AS, Tynan W. The human lumbar dorsal rami. J Anat. 1982;134(Pt 2):383–397.
Bogduk N. Clinical Anatomy of the Lumbar Spine and Sacrum, 5th ed. Churchill Livingstone Elsevier, 2012.
T11–12 facet → innervated by T10 and T11 medial branches
T12–L1 facet → innervated by T11 and T12 medial branches
🩺 Key rule: Each thoracic or lumbar facet joint receives dual innervation, from the medial branch at its own level and the level above.
Page updated
Google Sites
Report abuse